Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients

Dana-Farber Cancer Institute, Boston, MA
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Universita Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano
Willamette Valley Cancer Institute/US Oncology, Eugene, OR
St. James’s University Hospital, Leeds
University of Utah Huntsman Cancer Institute, Salt Lake City, UT
National Heart, Lung, and Blood Institute, Bethesda, MD
Maria Sklodowska-Curie National Research Institute of Oncology, Krakow
Swedish Cancer Institute, Seattle, WA
University of Texas MD Anderson Cancer Center, Houston, TX
AstraZeneca, South San Francisco, CA
AstraZeneca, South San Francisco, CA
AstraZeneca, Gaithersburg, MD
Vanderbilt University Medical Center, Nashville, TN
Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY
Vol. 107 No. 6 (2022): June, 2022